Stifel Financial’s AnaptysBio ANAB Stock Holding History

Stifel Financial’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-13,689	Closed	-$1.37M	–	2663
2018 Q3	$1.37M	Buy	+13,689	New	+$1.14M	﹤0.01%	1478

Other funds holding ANAB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Stifel Financial's ANAB Position: Q4 2018 in Review

Stifel Financial sold out of AnaptysBio (ANAB) in Q4 2018, closing a stake of 13,689 shares — an estimated $1.37M sold.

Stifel Financial first reported a position in ANAB in Q3 2018 and held it in 1 quarter. The position peaked at $1.37M in Q3 2018. 121 funds tracked by Wall St. Rank hold ANAB as of Q4 2018.

Stifel Financial reported no remaining AnaptysBio position as of Q4 2018 after selling out during the quarter.
Stifel Financial sold 13,689 AnaptysBio shares in Q4 2018, an estimated $1.37M.
Stifel Financial first reported a position in AnaptysBio in Q3 2018 and held it in 1 quarter.
Stifel Financial's AnaptysBio position peaked at $1.37M in Q3 2018.
121 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2018.

Based on Stifel Financial's 13F filing for Q4 2018, filed 13 Feb 2019.